News Release

December 17, 2019

RBM-007 Phase II Trial Registered in Clinical Trial Database

TOKYO, December 17, 2019 - RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TSE-Mothers: 4591, President and CEO: Yoshikazu Nakamura, Ph.D.) today announced that the outline of Phase II study of RBM-007 (anti-FGF2 aptamer) for treatment of wet age-related macular degeneration has been registered and published in ClinicalTrials.gov (*).

https://clinicaltrials.gov/ct2/show/NCT04200248

Contacts for inquiries or additional information:
RIBOMIC Inc.
Corporate Planning Department
ir.inquiry@ribomic.com

※ ClinicalTrials. gov is the world's largest clinical trial registration system operated by the National Institute of Health (NIH) and supported by the National Library of Medicine (NLM).